Abstract:Background Natural killer (NK) cells and T cells are important therapeutic populations that can target and eliminate cancer cells. Although human NK/T cell populations can be reconstituted in immunodeficient mice to test novel NK and/or T cell modulators, the time window for experimentation is often limited due to GvHD (graft-versus-host disease) complications. Moreover, human NK cell development and maturation is limited in such models due to the lack of human IL15. Previously, we disrupted the murine B2m allele in immunodeficient (B-NDG) mice and fused the FcRn coding region to the modified allele to ensure normal IgG metabolism, thereby generating B-NDG B2m KO mice plus. Here, we generated B-NDG B2m KO mice plus expressing human IL15 for improved NK cell engraftment and survival following human PBMC reconstitution. Methods We introduced the human IL15 coding sequence into the murine IL15 locus, and crossed the mice with B-NDG B2m KO mice plus to generate B-NDG B2m plus/hIL15 mice. Expression of B2m and IL15 protein in B-NDG B2m plus/hIL15 mice was evaluated using flow cytometry and ELISA, respectively. To assess human T cell and NK cell reconstitution, B-NDG B2m plus/hIL15 mice and B-NDG mice were engrafted with human PBMCs. To examine the engraftment capacity of hematopoietic stem cells (HSCs), B-NDG B2m plus/hIL15 or B-NDG hIL15 neonates were injected with human CD34+ cells (3E4) from mixed donors via the facial vein. Blood from engrafted mice was sampled for flow cytometric analysis. Survival and weight were recorded to monitor GvHD and incidence of other health-related effects. Results ELISA confirmed expression of human IL15, but not murine IL15 in B-NDG B2m plus/hIL15 mice. PBMC engraftment did not induce GvHD in B-NDG B2m plus/hIL15 mice over the 4 week study, while the survival rate of B-NDG mice was 20% after 2 weeks. Importantly, human T and NK cells were successfully reconstituted after PBMC engraftment. In newborn mice engrafted with CD34+ HSCs, higher levels of NK and myeloid cell reconstitution were observed in B-NDG B2m plus/hIL15 mice compared to B-NDG hIL15 mice. While all engrafted B-NDG hIL15 mice survived to 20 weeks, survival of B-NDG B2m KO/hIL15 mice dropped to 80% past week 12, and below 70% past week 18. Conclusions We established an immunodeficient humanized IL15 model that lacks B2m to reduce GvHD incidence upon PBMC engraftment. B-NDG B2m plus/hIL15 mice provide an ample therapeutic window for testing novel NK cell or T cell modulators in vivo. Ethics Approval All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Biocytogen Beijing Co., Ltd.

Generation of Inactivated IL2RG and RAG1 Monkeys with Severe Combined Immunodeficiency Using Base Editing

Biological Characteristics of Severe Combined Immunodeficient Mice Produced by CRISPR/Cas9-Mediated Rag2 and IL2rg Mutation

Talen-Based Generation of A Cynomolgus Monkey Disease Model for Human Microcephaly

Generation of a Monkey with MECP2 Mutations by TALEN-based Gene Targeting.

Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver

Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos

Generation of Recombination Activating Gene-1-Deficient Neonatal Piglets: A Model of T and B Cell Deficient Severe Combined Immune Deficiency

Dclre1c-Mutation-Induced Immunocompromised Mice Are a Novel Model for Human Xenograft Research

Cloning of a gene-edited macaque monkey by somatic cell nuclear transfer

RAG1/2 knockout pigs with severe combined immunodeficiency.

Generation of a Hutchinson–Gilford progeria syndrome monkey model by base editing

Novel Engraftment and T Cell Differentiation of Human Hematopoietic Cells in ART-/-IL2RG-/ Y SCID Pigs

Modeling Rett Syndrome Using TALEN-Edited MECP2 Mutant Cynomolgus Monkeys

Induction of core symptoms of autism spectrum disorder by in vivo CRISPR/Cas9-based gene editing in the brain of adolescent rhesus monkeys

16 A Novel B2m-deficient Immunodeficient Model Expressing Human IL15 for Preclinical Evaluation of T Cell and NK Cell-Based Therapies

Generation of SIV-resistant T cells and macrophages from nonhuman primate induced pluripotent stem cells with edited CCR5 locus

Engraftment of human iPS cells and allogeneic porcine cells into pigs with inactivated RAG2 and accompanying severe combined immunodeficiency

TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys.

Mutating PINK1 gene by paired truncated sgRNA/Cas9-D10A in Cynomolgus Monkey

A piggyBac-based platform for genome editing and clonal rhesus macaque iPSC line derivation

Using the BLT Humanized Mouse As a Stem Cell Based Gene Therapy Tumor Model